[Nonsteroidal anti-inflammatory drugs and the risk of polyposis, colon carcinoma and rectal carcinoma].
OBJECTIVE
To probe the risk of colorectal polyp, colon and rectal carcinoma and the intake of NSAIDs.


METHODS
Case-control study participants were from patients who underwent colonoscopy at different hospitals, the persons with the above disease was as cases, and those without the above diseases was as controls. Use of NSAIDs was assessed by interviewing the participants with a questionnaire which include a list of NSAIDs and related dietary and life style factors and family history.


RESULTS
There are 37 cases of colorectal polyp, 105 cases of colon carcinoma and 142 cases of rectal carcinoma and 66 controls. Adjusted for potential confounders, the risk of colorectal polyposis, colon carcinoma and rectal carcinoma were markedly reduced by NSAIDs. The OR values were 0.21 (95% CI 0.07-0.65, P = 0.007), 0.13 (95% CI 0.05-0.35, P < 0.001), 0.15 (95% CI 0.11-0.58, P < 0.001) respectively. The risk of the above diseases were also reduced markedly by aspirin, the OR values were 0.265 (95% CI 0.07-0.96, P = 0.044), 0.10 (95% CI 0.03-0.35, P < 0.001), 0.15 (95% CI 0.04-0.49, P = 0.002) respectively. The risk of colon carcinoma was also reduced by profen, with the OR being 0.11 (95% CI 0.02-0.64, P = 0.014).


CONCLUSIONS
Aspirin and other NSAIDs could reduced the risk of colorectal polyp, colon carcinoma and rectal carcinoma markedly. Aspirin was the most prospective chemopreventive agents for colorectal polyp, colon and rectal carcinoma for its capability of reducing the risk of cardio-cerebral vascular disease as well.
Gao
Xueqin
X
Shandong Academy of Medical Sciences, Jinan 250062, China.
Sun
Suling
S
Sun
Fangli
F
Li
Min
M
Sun
Huabin
H
Zhang
Weidong
W
Song
Shouqin
S
D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D001241:Aspirin / Q000627:therapeutic use; D015179:Colorectal Neoplasms / Q000517:prevention & control*; D005260:Female; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D016015:Logistic Models; D008297:Male; D008875:Middle Aged; D010894:Piroxicam / Q000627:therapeutic use; D011127:Polyps / Q000517:prevention & control*; D012004:Rectal Neoplasms / Q000517:prevention & control*; D012307:Risk Factors; D013467:Sulindac / Q000627:therapeutic use; D013997:Time Factors
D000894:Anti-Inflammatory Agents, Non-Steroidal; D010894:Piroxicam; D013467:Sulindac; D001241:Aspirin; D007052:Ibuprofen